Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

BACKGROUND: Chronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD) is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population. Few therapies have proved effective in modifying the increased CVD risk or rate...

Descripción completa

Detalles Bibliográficos

Autores principales:	Hill, Nathan R, Lasserson, Daniel, Thompson, Ben, Perera-Salazar, Rafael, Wolstenholme, Jane, Bower, Peter, Blakeman, Thomas, Fitzmaurice, David, Little, Paul, Feder, Gene, Qureshi, Nadeem, Taal, Maarten, Townend, Jonathan, Ferro, Charles, McManus, Richard, Hobbs, FD Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113231/ https://www.ncbi.nlm.nih.gov/pubmed/24886488 http://dx.doi.org/10.1186/1745-6215-15-160